Stockscreener 앱 받기
3.57
7.21%
0.24
시간 외 거래:
3.54
-0.03
-0.84%
전일 마감가:
$3.33
열려 있는:
$3.38
하루 거래량:
2.76M
Relative Volume:
0.78
시가총액:
$588.74M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-178.50
EPS:
-0.02
순현금흐름:
$-56.88M
1주 성능:
+9.51%
1개월 성능:
+11.91%
6개월 성능:
+379.65%
1년 성능:
+258.54%
1일 변동 폭
$3.36
$3.59
1주일 범위
$3.22
$3.59
52주 변동 폭
$0.40
$3.9099
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
3.57 | 549.16M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
Is CytomX Therapeutics Inc. (6C1) stock a buy on weaknessJuly 2025 Setups & Accurate Trade Setup Notifications - newser.com
How CytomX Therapeutics Inc. stock performs in rate cut cyclesJuly 2025 Update & Short-Term Trading Opportunity Alerts - newser.com
Using data filters to optimize entry into CytomX Therapeutics Inc.Analyst Downgrade & Entry and Exit Point Strategies - newser.com
What dividend safety rating applies to CytomX Therapeutics Inc. (6C1) stockBond Market & AI Forecasted Entry and Exit Points - newser.com
Published on: 2025-11-02 12:38:04 - newser.com
What insider purchases suggest about CytomX Therapeutics Inc. (6C1) stockMarket Sentiment Review & Daily Momentum Trading Reports - newser.com
Key metrics from CytomX Therapeutics Inc.’s quarterly data2025 Earnings Surprises & Technical Buy Zone Confirmations - newser.com
Why CytomX Therapeutics Inc. (6C1) stock is a strong buy callJuly 2025 Final Week & Real-Time Volume Spike Alerts - newser.com
What earnings margins imply for CytomX Therapeutics Inc. (6C1) stockJuly 2025 Intraday Action & Daily Volume Surge Signals - newser.com
Using Ichimoku Cloud for CytomX Therapeutics Inc. technicalsQuarterly Portfolio Report & Long-Term Capital Growth Strategies - newser.com
How to integrate CytomX Therapeutics Inc. into portfolio analysis tools2025 Trade Ideas & Low Drawdown Trading Strategies - newser.com
How CytomX Therapeutics Inc. stock reacts to oil pricesJuly 2025 Short Interest & Weekly Return Optimization Alerts - newser.com
Why analysts maintain buy rating on CytomX Therapeutics Inc. (6C1) stockShort Setup & Real-Time Volume Triggers - newser.com
What drives CytomX Therapeutics Inc 6C1 stock priceMarket Sentiment Report & Trusted Financial Advisors at No Cost - earlytimes.in
Is CytomX Therapeutics Inc. (6C1) stock considered safe havenTrade Analysis Summary & Free Technical Pattern Based Buy Signals - newser.com
CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Building trade automation scripts for CytomX Therapeutics Inc.2025 Macro Impact & AI Driven Stock Movement Reports - newser.com
Can CytomX Therapeutics Inc. stock reach $100 price targetJuly 2025 Update & AI Forecast Swing Trade Picks - newser.com
How CytomX Therapeutics Inc. stock compares to market leadersJuly 2025 Summary & Real-Time Stock Price Movement Reports - newser.com
What analyst consensus implies for CytomX Therapeutics Inc. (6C1) stock2025 Trading Volume Trends & Weekly High Potential Alerts - newser.com
Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX), Sets a $7 PT - MSN
Will CytomX Therapeutics Inc. stock reach Wall Street targetsPortfolio Update Report & Breakout Confirmation Trade Signals - newser.com
CytomX Therapeutics, Inc. to Report Third Quarter Financial Results on November 6, 2025 - Quiver Quantitative
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
CytomX Therapeutics (NASDAQ: CTMX) sets third-quarter results for Nov. 6, with webcast - Stock Titan
Published on: 2025-10-30 05:08:21 - newser.com
Visual analytics tools that track CytomX Therapeutics Inc. performanceMarket Sentiment Report & Technical Pattern Alert System - newser.com
CytomX (CTMX) reports 650,000 CBO stock options at $3.74 - Stock Titan
CTMX insider filing: Form 3 shows zero beneficial ownership - Stock Titan
How CytomX Therapeutics Inc. (6C1) stock behaves in tightening cyclesGlobal Markets & Community Trade Idea Sharing Platform - newser.com
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.62%
0.21%
자본화:
|
볼륨(24시간):